SCHEMBL3860554

SCHEMBL3860554

COc1cc([N+](=O)[O-])ccc1OCCN1CCCC1CO

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 3/20 0.51
▸ CYP3A4 P08684 3/20 0.51
▸ CYP2D6 P10635 3/20 0.51
▸ KCNH2 Q12809 2/20 0.51
▸ ALDH1A1 P00352 6/20 0.44
▸ CHRNB4 P30926 1/20 0.44
▸ CHRNA3 P32297 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ SPHK1 Q9NYA1 1/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ MAPT P10636 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3860546 1.00 MCHR1 (0.51) MCHR1CYP3A4CYP2D6KCNH2ALDH1A1
SCHEMBL5381743 0.86 HRH3 (0.56) CYP3A4CYP2D6ALDH1A1CHRM1SMN1; SMN2
SCHEMBL5388625 0.83 HRH3 (0.52) MCHR1CYP3A4CYP2D6ALDH1A1SMN1; SMN2
SCHEMBL5260737 0.83 CHRNB4 (0.56) CYP3A4CYP2D6ALDH1A1CHRNB4CHRNA3
SCHEMBL6204091 0.82 ALDH1A1 (0.45) MCHR1CYP3A4CYP2D6ALDH1A1SMN1; SMN2
SCHEMBL7972052 0.82 SPHK1 (0.49) CYP2D6ALDH1A1SPHK1SMN1; SMN2MAPT
SCHEMBL3861170 0.81 MCHR1 (0.55) MCHR1CYP3A4CYP2D6KCNH2ALDH1A1
SCHEMBL3861164 0.81 MCHR1 (0.55) MCHR1CYP3A4CYP2D6KCNH2ALDH1A1
Hydrochloric Acid SCHEMBL7603830 0.81 SPHK1 (0.49) CYP2D6ALDH1A1SPHK1SMN1; SMN2MAPT
SCHEMBL5257833 0.79 CHRNB4 (0.66) MCHR1CHRNB4CHRNA3CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592373-B2 Amide compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 — — US disclosed
EP-1708698-A1 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-10-11 — — EP disclosed
WO-2005063239-A9 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS BOEHRINGER INGELHEIM INT (DE) 2006-03-09 — — WO disclosed
US-20050267093-A1 Amide compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-01 — — US disclosed
WO-2005063239-A1 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267093-A1 Amide compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, MC4R, MCHR2 MCHR1 1/4885CYP3A4 4287/4885CYP2D6 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback